Long-term safety study for people with lung fibrosis
Part of Lungs & breathing clinical trials.
This study is for people who have completed an earlier clinical trial for pulmonary fibrosis. It checks the long-term safety and tolerability of the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier studies (IM027068 or IM0271015) and not stopped the study drug permanently due to side effects.
- You must not have any medical condition that, in the doctor's judgment, would make it unsafe for you to participate.
- You must not have symptoms of heart failure when resting.
- You must not have had lung reduction surgery or a lung transplant.
- If you have pulmonary arterial hypertension (high blood pressure in the lungs), you must not have recently switched from a single medication to multiple medications for it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two medications, nerandomilast and mycophenolate, helps people with different types of pulmonary fibrosis (lung scarring). It aims to see if this combination is safe and works well for various subtypes other than IPF.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
This study tests whether advanced MRI scans can better detect and track lung scarring in people with certain types of pulmonary fibrosis. It may help doctors understand how well your treatment is working, without extra radiation from CT scans.
This study looks at how patients and doctors decide on treatment for pulmonary fibrosis. It aims to understand the impact of side effects from antifibrotic medicines on treatment choices.
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.